|
EP2848242A1
|
|
Orally disintegrating formulations of Linagliptin
|
|
EP2848241A1
|
|
Effervescent formulations of linagliptin
|
|
EP2832351A1
|
|
Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
|
|
EP2829269A1
|
|
Orally Disintegrating Tablet Formulation Comprising Flurbiprofen
|
|
WO2015007890A1
|
|
Pharmaceutical combinations of pregabalin
|
|
EP2815743A1
|
|
Ceftibuten formulations
|
|
WO2014191414A1
|
|
Syrup formulation of salbutamol
|
|
WO2014180912A1
|
|
Modified release formulations of lacosamide
|
|
EP2783680A1
|
|
Controlled-release formulations comprising metformin and gliclazide
|
|
WO2014154643A1
|
|
Extended release formulations of metformin
|
|
WO2014125085A1
|
|
Oral pharmaceutical formulations comprising nimesulide and thiocolchicoside
|
|
WO2014060560A1
|
|
Solid oral formulations of prasugrel
|
|
EP2722033A1
|
|
Pharmaceutical Compositions of Dabigatran Free Base
|
|
WO2014060554A1
|
|
Prasugrel formulations
|
|
WO2014057059A1
|
|
Effervescent cefdinir formulation
|
|
WO2014027982A2
|
|
Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
|
|
WO2014027981A2
|
|
Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
|
|
WO2014027979A2
|
|
Tablet formulations comprising tadalafil and dapoxetine
|
|
US2015202168A1
|
|
Oral film formulations comprising dapoxetine and tadalafil
|
|
WO2014027975A2
|
|
Novel orally administered pharmaceutical formulations
|
